Foyston Gordon & Payne Inc purchased a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) in the 2nd quarter, Holdings Channel reports. The firm purchased 75,481 shares of the company’s stock, valued at approximately $6,304,000.
Other institutional investors have also made changes to their positions in the company. Ameriprise Financial Inc. grew its position in Henry Schein by 3,275.2% in the second quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares in the last quarter. Bank of Montreal Can increased its position in shares of Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares during the last quarter. Norges Bank acquired a new position in Henry Schein during the fourth quarter valued at approximately $88,116,000. Southpoint Capital Advisors LP grew its stake in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after purchasing an additional 700,000 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after purchasing an additional 668,182 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.
Analysts Set New Price Targets
Several analysts have issued reports on HSIC shares. Barclays reaffirmed an “overweight” rating and set a $100.00 price target (up from $86.00) on shares of Henry Schein in a research report on Thursday, August 6th. Stifel Nicolaus set a $95.00 price target on Henry Schein in a report on Wednesday, August 5th. Mizuho decreased their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Barrington Research set a $104.00 target price on shares of Henry Schein in a report on Wednesday, August 5th. Finally, Citigroup reiterated a “buy” rating and issued a $112.00 price target (up from $100.00) on shares of Henry Schein in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Henry Schein presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.93.
Henry Schein Stock Performance
Henry Schein stock opened at $88.50 on Friday. The business has a 50 day moving average of $85.74 and a 200-day moving average of $79.52. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73. Henry Schein, Inc. has a 1 year low of $61.94 and a 1 year high of $92.18. The company has a market capitalization of $9.86 billion, a P/E ratio of 25.80, a P/E/G ratio of 1.69 and a beta of 0.80.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.03. The firm had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the firm earned $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. On average, equities research analysts predict that Henry Schein, Inc. will post 5.35 earnings per share for the current year.
Henry Schein Profile
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Stories
- Five stocks we like better than Henry Schein
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
